20-22 August 2018

San Francisco, CA

Register by Friday, June 15 to Save $400

Day One
Tuesday 21 August, 2018

Day Two
Wednesday 22 August, 2018

Chair’s Opening Remarks

IPF: Recent Advances & the Future Landscape

Keynote: IPF: Where are we now?


  • Highlighting progress from IPF Summit 2017 including advancement of the standardization of imaging
  • Reviewing the IPF drug development landscape
  • Outlining outcomes for the 2nd IPF Summit from the outset

Beyond Bleomycin: More Confidently Utilizing Preclinical Models

Beyond Bleomycin: The Nintedanib Experience

  • Gerald Nabozny Executive Director Inflammation, Immunology & Respiratory Disease Research, Boehringer Ingelheim


  • Exploring the mode of action of Nintedanib using a broad and diverse set of cellular models
  • Discussing in vivo models with diverse triggers
  • Sharing what was learned about Nintedanib activity in preclinical models

Speed Networking


This session is the ideal opportunity to get face-to-face time with many of the brightest minds working in the IPF  ield and establish meaningful business relationships to pursue for the rest of the conference.

Morning Refreshments

Targeting Translational Failings Through Use of Non-Invasive Imaging & Biomarkers

Regional Disease Progression & Quantification of Interstitial Lung Diseases Using Functional Respiratory Imaging


  • Outlining Functional Respiratory Imaging for use in IPF
  • Demonstrating the value of quantitative CT imaging in IPF drug development
  • Highlighting imaging use to show regional disease state and expression
  • Discussing imaging associated biomarkers within IPF

Leveraging Biomarker Data for Dose Selection


  • Outlining biomarker selection in IPF and associations with the TGFβ pathway
  • Showcasing preclinical data outlining doses to inhibit fibrosis in animal models
  • Analyzing human studies at 8 weeks for extent of TGFβ inhibition and rationale behind dose selection

Lunch & Networking

Next Generation of IPF Clinical Trials: Evaluating Trial Design

IPF: An Orphan Disease with Successful Phase 3 Trials!

  • John Moran Chief Medical Officer, Prometic Biosciences


  • Overcoming the challenges of designing a phase 3 trial with limited prior trial data in an orphan disease
  • Good news: For IPF we have a legion of data from pivotal phase 3 studies
  • Bad news: For IPF there are two approved drugs

Think Tank Round Table Discussions: What Does the Next Generation of Phase 3 Clinical Trials Look Like?


More practical and highly interactive breakout roundtables where attendees can crowd-source solutions and share opinions around pre-assigned topic areas. A valuable chance for attendees to unite around hot topics, debate best practice and share experiences to identify solutions.


What benefits will
payers need to
see to consider a
new therapeutic &
how do we design
clinical trials to
best demonstrate


Can imaging
be accepted
as a secondary


How do we get
predictive reads
of efficacy with
smaller sample
sets to then draw
predictions for
large sample


How do we
overcome an
adverse safety
profile from a
standard of care
when running
phase 3 trials for a
new candidate?


Moderator Feedback & Audience Debate


Moderators will be assigned to each roundtable to facilitate discussion and collate the findings.
Following the roundtables, they will present back to the entire delegation as part of information dissemination and opening up the wider audience debate.

Afternoon Refreshments & Networking

Rho-Associated Coiled-Coil Kinase 2 (ROCK2) Inhibition in IPF

  • John Ryan Executive Vice President & Chief Medical Officer, Kadmon


  • Outlining therapeutic potential of ROCK inhibition in regulating pro-fibrotic processes
  • Sharing the ongoing clinical development of KD025 in IPF

Taking Advantage of Human Genetics for Preclinical & Clinical Decisions

Genetic & Genomic Considerations in IPF Clinical Trials

  • David Schwartz Professor of Medicine & Immunology, University of Colorado-Denver


  • Outlining IPF as a heterogeneous disease caused by multiple gene variants
  • Demonstrating the distinct clinical course for each type of IPF
  • Showing how drug trials should control the disease heterogeneity in IPF

Panel Discussion: Precision Medicine in IPF – Using Genetics to Inform Patient Stratification Decisions for Clinical Trials

  • Timothy Blackwell Professor of Cell & Developmental Biology, Vanderbilt University Medical Center
  • Fernando Martinez Executive Vice Chair of Medicine, Weill Cornell Medical College
  • David Schwartz Professor of Medicine & Immunology, University of Colorado-Denver


Shared insights from key opinion leaders with a focus on:

  • Outlining what is known about inherited genetic factors and their influence in the development of IPF
  • Hypothesizing how future studies will characterize patient phenotypes and how they will influence trial design and outcome
  • Understanding the influence of genetics and precision therapeutics on clinical decision-making regarding IPF diagnosis and treatment

Chair’s Closing Remarks

Scientific Poster Session


After the formal presentations have finished, the learning and networking carries on.
The Poster Session allows you to connect with your peers in a relaxed atmosphere and continue to forge new and existing relationships.